PETALUMA, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) ("RetinalGeniX" or the "Company") today announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer.
The Company is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
Mr. Ahluwalia is a seasoned executive and joins RetinalGeniX Technologies Inc. with over 15 years of experience in finance and operations across public and private organizations. He holds an MBA in Finance from Northeastern University and a Bachelor of Science from the National Institute of Technology (NIT) at Kurukshetra University. His proven track record in high-growth environments includes capital raises and accounting.
RetinalGeniX is developing innovative technologies such as DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to prevent blindness through the early detection and treatment of ocular diseases.
In concert with its Pharmaco-Genetic Mapping™ the Company is developing a high-resolution retinal home and remote monitoring system that is intended to offer 24/7 real-time alerts to both physicians and patients and a cost-effective high-resolution retinal mass screening device that does not require dilation of the pupil. The combined technologies are intended to prevent blindness through the early detection and treatment of ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
The Company has started conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer's/Dementia complex as part of its DNA/RNA/GPS™ initiative.
RetinalGeniX has also filed two provisional patents related to these ...